PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1279777
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1279777
Global Psychedelic Drugs Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Psychedelic drugs, also known as hallucinogens, are a class of psychoactive substances that alter perception, mood, and cognitive processes. They produce profound changes in thought, mood, and sensory perception, often inducing altered states of consciousness, mystical experiences, and intense emotions. Common examples of psychedelic drugs include LSD, psilocybin mushrooms, mescaline, DMT, and ayahuasca. The Psychedelic Drugs market is expanding because of factors such as government initiatives, alliances, and awareness programs associated with mental health and rise in research and development of psychedelic drugs.
One of the main drivers of market expansion during the forecast period is the prevalence of mental health difficulties, which call for the use of psychedelic medications to treat conditions like anxiety and depression, psychosis, and some types of panic attacks. For instance, according to the State of Mental Health in America 2022 report, there were 197,000 more young people who had a severe major depressive episode (MDE) than there were in the 2021 dataset. As a result, the rising prevalence of depressive disorders fuels a rise in the demand for psychedelic medications, which in turn spurs market expansion over the projection period. Furthermore, a rise in product approvals and rising development of psychedelic drugs research center. In addition, a rise in product approvals and rising development of psychedelic drugs research centre is creating a lucrative growth to the market. However, high number of side effects of psychedelic drug and stringent regulatory framework for drug marketing stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Psychedelic Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Type offerings of key players. The detailed segments and sub-segment of the market are explained below.
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable